Tau PET in Imaging and Cognition: Healthy Adults From 55-90
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in
cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then
examine the interactions between differential tau burden and performance on cognitive tasks,
functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive
and behavioral measures. By investigating these relationships, the investigators hope to
understand the cognitive and behavioral outcomes of tau deposition found in specific brain
regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims
to examine how the presence of tau may contribute to the risk of subsequent cognitive
decline, neurodegeneration, and dementia.